Currently recruiting gastro-intestinal trials
Protocol: C4221022 (PI: Dr Warren Joubert)
Protocol Title: A Phase 2, Randomized, Open-Label Study of Encorafenib and Cetuximab Plus Pembrolizumab Versus Pembrolizumab alone in Participants with Previously Untreated BRAF V600E-Mutant, MSI-H/DMMR Metastatic Colorectal Cancer
Lay Title: A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
Click here for more information
Protocol: CA224-123 (PI: Dr Warren Joubert)
Protocol Title: Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)
Lay Title: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
PROTOCOL: EF-27 (PANOVA-3) (PI: DR Warren Joubert)
Protocol Title: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Lay Title: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel